Alopexx sets $10 to $12 IPO range, targeting $33 million raise
As seen on the 24/7 Wall St. homepage on September 17, 2026.
Alopexx sets $10-$12 range for $33 million NYSE American IPO
Nineteen amendments in, Alopexx finally has hard terms: 3 million shares at $10 to $12, or about $33 million on NYSE American with ThinkEquity running the book. A concrete range after a four-year registration slog is the signal that pricing is close.
Continue ReadingShow less
Alopexx, Inc. has filed an amended S-1 that carries a concrete price range for the first time, targeting roughly $33 million in gross proceeds on NYSE American.
The registration process was unusually protracted, requiring nineteen amendments before the company and its underwriter landed on firm terms, and a priced range signals the extended SEC review is substantively resolved.
Sponsored
Are You Ready To Retire, Or Years Behind?
Most Americans suspect they're behind on retirement and never find out. Advisor.com's free matching tool pairs you in about three minutes with a vetted fiduciary advisor who can help you with investing, taxes, retirement, estate planning, and more. No minimums. No sales call. Find out where you stand.
ThinkEquity, which specializes in smaller growth offerings, is running the book, and investors watching the NYSE American small-cap pipeline should treat the concrete range as the clearest indication yet that a road show and final pricing are imminent.
No final price has been set as of the filing date, and the SEC filing remains the authoritative source for full terms, risk factors, and use of proceeds.